CN111467472A - 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用 - Google Patents
一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用 Download PDFInfo
- Publication number
- CN111467472A CN111467472A CN202010316985.4A CN202010316985A CN111467472A CN 111467472 A CN111467472 A CN 111467472A CN 202010316985 A CN202010316985 A CN 202010316985A CN 111467472 A CN111467472 A CN 111467472A
- Authority
- CN
- China
- Prior art keywords
- tumor
- peptide
- cell lymphoma
- preparation
- targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010316985.4A CN111467472B (zh) | 2020-04-21 | 2020-04-21 | 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010316985.4A CN111467472B (zh) | 2020-04-21 | 2020-04-21 | 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111467472A true CN111467472A (zh) | 2020-07-31 |
CN111467472B CN111467472B (zh) | 2020-12-25 |
Family
ID=71756006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010316985.4A Active CN111467472B (zh) | 2020-04-21 | 2020-04-21 | 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111467472B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111925448A (zh) * | 2020-08-03 | 2020-11-13 | 山东大学 | 在体生成car-巨噬细胞的制备方法及肿瘤免疫治疗中的应用 |
CN114225047A (zh) * | 2021-12-13 | 2022-03-25 | 安徽医科大学 | 一种免疫逃逸纳米制剂、制备方法及应用 |
CN114642768A (zh) * | 2020-12-18 | 2022-06-21 | 深圳先进技术研究院 | 一种调控巨噬细胞极化和免疫功能的材料及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102573500A (zh) * | 2009-08-06 | 2012-07-11 | 纽拉尔图斯制药公司 | 巨噬细胞相关疾病的治疗 |
CN103998935A (zh) * | 2011-04-28 | 2014-08-20 | 斯隆-凯特林癌症研究所 | Hsp90组合疗法 |
CN106573070A (zh) * | 2014-08-13 | 2017-04-19 | 约翰霍普金斯大学 | 树枝状聚合物到脑肿瘤的选择性传递 |
CN107573418A (zh) * | 2017-08-21 | 2018-01-12 | 华中科技大学 | 肿瘤相关巨噬细胞双靶向多肽、纳米颗粒、制备及应用 |
CN108064295A (zh) * | 2015-01-14 | 2018-05-22 | 埃克西奎雷股份有限公司 | 具有核心基序的核酸纳米结构 |
CN110831979A (zh) * | 2017-03-31 | 2020-02-21 | 酵活有限公司 | 肿瘤抗原递呈诱导物构建体及其用途 |
-
2020
- 2020-04-21 CN CN202010316985.4A patent/CN111467472B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102573500A (zh) * | 2009-08-06 | 2012-07-11 | 纽拉尔图斯制药公司 | 巨噬细胞相关疾病的治疗 |
CN103998935A (zh) * | 2011-04-28 | 2014-08-20 | 斯隆-凯特林癌症研究所 | Hsp90组合疗法 |
CN106573070A (zh) * | 2014-08-13 | 2017-04-19 | 约翰霍普金斯大学 | 树枝状聚合物到脑肿瘤的选择性传递 |
CN108064295A (zh) * | 2015-01-14 | 2018-05-22 | 埃克西奎雷股份有限公司 | 具有核心基序的核酸纳米结构 |
CN110831979A (zh) * | 2017-03-31 | 2020-02-21 | 酵活有限公司 | 肿瘤抗原递呈诱导物构建体及其用途 |
CN107573418A (zh) * | 2017-08-21 | 2018-01-12 | 华中科技大学 | 肿瘤相关巨噬细胞双靶向多肽、纳米颗粒、制备及应用 |
Non-Patent Citations (5)
Title |
---|
KIRYEONG KIM等: "Inhibitory Effect of Purpurogallin on Osteoclast Differentiation In Vitro through the Downregulation of c-Fos and NFATc1", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》 * |
MARYELISE CIESLEWICZ等: "Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival", 《PNAS》 * |
SOBIYAZAFAR等: "Novel therapeutic interventions in cancer treatment using protein and peptide-based targeted smart systems", 《SEMINARS IN CANCER BIOLOGY》 * |
WARD,L.M 等: "excinuclease ABC subunit A [Candidatus Parcubacteria bacterium]", 《GENBANK》 * |
黄芳: "氯氰菊酯对巨噬细胞的毒性作用和极化的影响及其相关机制", 《中国博士学位论文全文数据库医药卫生科技辑》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111925448A (zh) * | 2020-08-03 | 2020-11-13 | 山东大学 | 在体生成car-巨噬细胞的制备方法及肿瘤免疫治疗中的应用 |
CN114642768A (zh) * | 2020-12-18 | 2022-06-21 | 深圳先进技术研究院 | 一种调控巨噬细胞极化和免疫功能的材料及其应用 |
CN114642768B (zh) * | 2020-12-18 | 2023-01-03 | 深圳先进技术研究院 | 一种调控巨噬细胞极化和免疫功能的材料及其应用 |
CN114225047A (zh) * | 2021-12-13 | 2022-03-25 | 安徽医科大学 | 一种免疫逃逸纳米制剂、制备方法及应用 |
CN114225047B (zh) * | 2021-12-13 | 2023-12-26 | 安徽医科大学 | 一种免疫逃逸纳米制剂、制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111467472B (zh) | 2020-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111467472B (zh) | 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用 | |
CN104434812A (zh) | 一种柞蚕丝素蛋白阿霉素缓释微球及其制备方法 | |
CN116103205B (zh) | 一种粘液玫瑰单胞菌、菌剂和胞外多糖及其制备方法和应用 | |
Mi et al. | Postsurgical wound management and prevention of triple-negative breast cancer recurrence with a pryoptosis-inducing, photopolymerizable hydrogel | |
Zhang et al. | Preparation and characterization of layer-by-layer hypoglycemic nanoparticles with pH-sensitivity for oral insulin delivery | |
CN111905105A (zh) | 一种用于癌症靶向治疗的蛋白类纳米药物及其制备方法 | |
CN113444785B (zh) | 一种与仔猪C型产气荚膜梭菌感染性腹泻相关的ssc-miR-122-5p及其应用 | |
CN113144200B (zh) | 一种setd4蛋白抑制剂在制备激活休眠肿瘤细胞药物中的应用 | |
CN107217041B (zh) | 具有高抗原呈递的dc细胞和抗原特异性t细胞及其制备方法和应用 | |
CN110755607B (zh) | 氧化锌、抗原共载药物纳米疫苗、其制备方法与应用 | |
CN113181136B (zh) | 一种装载和递送核酸的复合颗粒及其制备方法和用途 | |
CN102060910B (zh) | 锌转运蛋白8的hla-a*0201限制性ctl表位及其应用 | |
KR101571231B1 (ko) | 가용성 셀레노당단백질을 분리, 특성화 및 투여하기 위한 조성물 및 방법 | |
CN114225008B (zh) | 转录因子btb-cnc同源体1在非霍奇金淋巴瘤治疗中的应用 | |
CN111001014A (zh) | 一种基于固定细菌做载体的抗肿瘤药物及其应用 | |
CN116515762A (zh) | 一种促进糖尿病创面愈合的工程化改造外泌体及其制备方法和应用 | |
CN111388499A (zh) | miR-31在制备预防和治疗溃疡性结肠炎的结肠靶向纳米药物中的应用 | |
CN109402075A (zh) | 一种用于清除氧自由基的小分子蛋白质及其应用 | |
CN114099417B (zh) | 中性粒细胞胞外杀菌网络响应性载药凝胶及其制法和使法 | |
CN114558141A (zh) | 降低胰腺癌细胞恶性表型的促进剂、药物组合及其用途 | |
WO2017071379A1 (zh) | 一种用于治疗胃癌的肿瘤疫苗及其制备方法 | |
CN104922698B (zh) | 人干细胞生长因子注射液及其制备方法 | |
CN109432050A (zh) | 一种自然杀伤细胞外泌体和大分子树枝状聚合物的组合物 | |
CN112870224B (zh) | 一种放疗增敏剂及其制备方法 | |
CN110064046B (zh) | 微肽yy1bm在治疗癌症中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221019 Address after: 450000 building 11, Zhengzhou airport biomedical park, northeast corner of the intersection of Huanghai Road and biotechnology Second Street, Hangkong port area, Zhengzhou City, Henan Province Patentee after: Zhengzhou Yuanchuang Gene Technology Co.,Ltd. Patentee after: Henan Yuanchuang life stem cell bank technology Co.,Ltd. Address before: Room 2407, Block C, Jiaqiao International Plaza, Baohe District, Hefei City, Anhui Province, 230000 Patentee before: Hefei Tingyi Environmental Protection Technology Co.,Ltd. Effective date of registration: 20221019 Address after: Room 2407, Block C, Jiaqiao International Plaza, Baohe District, Hefei City, Anhui Province, 230000 Patentee after: Hefei Tingyi Environmental Protection Technology Co.,Ltd. Address before: No.282 Hanzhong Road, Nanjing, Jiangsu Province 210023 Patentee before: Nanjing University of Chinese Medicine |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20200731 Assignee: Zhengzhou Bain Biotechnology Co.,Ltd. Assignor: Zhengzhou Yuanchuang Gene Technology Co.,Ltd.|Henan Yuanchuang life stem cell bank technology Co.,Ltd. Contract record no.: X2023980034401 Denomination of invention: An immunomodulatory microsphere formulation targeting tumor associated macrophages and its preparation method and application Granted publication date: 20201225 License type: Common License Record date: 20230403 |